Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
42
OPT Quote, Financials, Valuation and Earnings
Last price:
$3.65
Seasonality move
:
-5.59%
Day range:
$3.54 - $3.63
52-week range:
$1.79 - $5.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,322.88x
P/B ratio:
--
Volume:
3K
Avg. volume:
21.7K
1-year change:
49.69%
Market cap:
$558.6M
Revenue:
$124.7K
EPS (TTM):
-$2.76
Analysts' Opinion
-
Consensus RatingOpthea has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.17, Opthea has an estimated upside of 235.17% from its current price of $3.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $3.63.
Fair Value
-
According to the consensus of 5 analysts, Opthea has 235.17% upside to fair value with a price target of $12.17 per share.
OPT vs. S&P 500
-
Over the past 5 trading days, Opthea has overperformed the S&P 500 by 8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Opthea does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Opthea has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Opthea reported revenues of --.
Earnings Growth
-
Opthea has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Opthea reported earnings per share of --.
Enterprise value:
527.7M
EV / Invested capital:
--
Price / LTM sales:
2,322.88x
EV / EBIT:
--
EV / Revenue:
4,232.85x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-145.56%
Net Income Margin (TTM):
-176665.74%
Return On Equity:
--
Return On Invested Capital:
-669.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2017-06-30 | 2018-06-30 | 2019-06-30 | 2018-06-30 | 2019-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$7.5M | -$21.9M | -$26.2M | -- | -- | |
| EBITDA | -$7.5M | -$21.9M | -$26.2M | -- | -- | |
| Diluted EPS | -$0.21 | -$0.43 | -$0.45 | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49M | $138.1M | $59.9M | $98.4M | $188.2M | |
| Total Assets | $49.4M | $138.4M | $60M | $98.6M | $188.8M | |
| Current Liabilities | $4.8M | $3.1M | $12M | $18.7M | $64.1M | |
| Total Liabilities | $4.9M | $3.1M | $12.1M | $104.5M | $264.6M | |
| Total Equity | $44.6M | $135.3M | $48M | -$5.9M | -$75.8M | |
| Total Debt | -- | -- | -- | $85.7M | $141.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -$11K | |
| Cash From Financing | -- | -- | -- | -- | $34.8M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
OPT
Sector
Market Cap
$558.6M
$46.1M
Price % of 52-Week High
66.61%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-78.23%
-0.6%
1-Year Price Total Return
49.69%
-30.52%
Beta (5-Year)
0.742
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.35
200-day SMA
Buy
Level
$3.26
Bollinger Bands (100)
Buy
Level
2.81 - 4.35
Chaikin Money Flow
Sell
Level
-4.9M
20-day SMA
Buy
Level
$3.48
Relative Strength Index (RSI14)
Buy
Level
53.67
ADX Line
Buy
Level
24.04
Williams %R
Neutral
Level
-23.559
50-day SMA
Sell
Level
$3.85
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
3.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.3974)
Sell
CA Score
(Annual)
Level (-10.3201)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (10.9036)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
Stock Forecast FAQ
In the current month, OPT has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OPT average analyst price target in the past 3 months is $12.17.
-
Where Will Opthea Stock Be In 1 Year?
According to analysts, the consensus estimate is that Opthea share price will rise to $12.17 per share over the next 12 months.
-
What Do Analysts Say About Opthea?
Analysts are divided on their view about Opthea share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Opthea is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Opthea's Price Target?
The price target for Opthea over the next 1-year time period is forecast to be $12.17 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Opthea is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OPT?
You can purchase shares of Opthea via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Opthea shares.
-
What Is The Opthea Share Price Today?
Opthea was last trading at $3.65 per share. This represents the most recent stock quote for Opthea. Yesterday, Opthea closed at $3.63 per share.
-
How To Buy Opthea Stock Online?
In order to purchase Opthea stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
